Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs

Inclusion Criteria:

- Clinical diagnosis of untreated breast cancer, treated (advance stage) or untreated
colon cancer, untreated non-Hodgkins lymphoma, or advanced gastroesophageal cancer
scheduled to begin chemotherapy with either Taxol, oxaliplatin, or vincristine

Exclusion Criteria:

- Individuals with an implanted electronic medical devices (cardiac pacemaker or
defibrillator, vagus nerve stimulator, deep brain stimulator, intrathecal pump,
others)

- Individuals whose chemotherapy regimen will include nerve toxic drugs other than
Taxol, oxaliplatin, or vincristine, or includes more than one of these three drugs in
combination

- Individuals whose screening nerve conduction studies show peroneal motor amplitude <
1 mV bilaterally or sural sensory amplitude < 3 uV bilaterally or no result
obtainable